Tg Therapeutics Q3 2026 Results: Net Income $55.5M, Down 85.8% YoY
TG Therapeutics is focused on the commercialization of BRIUMVI for relapsing forms of multiple sclerosis and the development of its subcutaneous formulation and azer-cel. The company has a history of losses but is utilizing its commercial infrastructure to expand market acceptance while managing significant debt obligations and clinical trial expenses.
- Key figure
- Net income $55.5M · -85.8% YoY